A single phosphorodiamidate morpholino oligomer targeting VP24 protects rhesus monkeys against lethal ebola virus infection

mBio

Volumn 6, Issue 1, 2015, Pages

  Warren, Travis K ^a   Whitehouse, Chris A ^a   Wells, Jay ^a   Welch, Lisa ^a   Heald, Alison E ^b,c   Charleston, Jay S ^b   Sazani, Pete ^b   Reid, St Patrick ^a   Iversen, Patrick L ^b,d   Bavari, Sina ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b AVI BIOPHARMA INC   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d OREGON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; AVI 6002; AVI 7537; AVI 7539; MORPHOLINO OLIGONUCLEOTIDE; PROTEIN VP24; UNCLASSIFIED DRUG; VIRULENCE FACTOR; VIRAL PROTEIN; VP24 PROTEIN, EBOLA VIRUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG TARGETING; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; FEMALE; INFECTION PREVENTION; MALE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; EBOLAVIRUS; GENETICS; HEMORRHAGIC FEVER, EBOLA; HUMAN; METABOLISM; VIROLOGY;

EBOLA VIRUS; MACACA MULATTA; PRIMATES;

ANIMALS; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; HUMANS; MACACA MULATTA; MORPHOLINOS; VIRAL PROTEINS;

EID: 84924122562     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.02344-14     Document Type: Article

References (16)

1. Feldmann H, Geisbert TW. 2011. Ebola haemorrhagic fever. Lancet 377: 849-862. http://dx. doi. org/10. 1016/S0140-6736(10)60667-8.
2. Baize S, Pannetier D, Oestereich L, Rieger T, Koivogui L, Magassouba N, Soropogui B, Sow MS, Keita S, De Clerck H, Tiffany A, Dominguez G, Loua M, Traore A, Kolie M, Malano ER, Heleze E, Bocquin A, Mely S, Raoul H, Caro V, Cadar D, Gabriel M, Pahlmann M, Tappe D, Schmidt-Chanasit J, Impouma B, Diallo AK, Formenty P, Van Herp M, Gunther S. 2014. Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med 371: 1418-1425. http://dx. doi. org/10. 1056/NEJMoa1404505.
3. Gostin LO, Lucey D, Phelan A. 2014. The Ebola epidemic: A global health emergency. JAMA 312: 1095-1096. http://dx. doi. org/10. 1001/jama. 2014. 11176.
4. Borio L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes JM, Jahrling PB, Ksiazek T, Johnson KM, Meyerhoff A, O'Toole T, Ascher MS, Bartlett J, Breman JG, Eitzen EM, Jr., Hamburg M, Hauer J, Henderson DA, Johnson RT, Kwik G, Layton M, Lillibridge S, Nabel GJ, Osterholm MT, Perl TM, Russell P, Tonat K, Working Group on Civilian Biodefense. 2002. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 287: 2391-2405. http://dx. doi. org/10. 1001/jama. 287. 18. 2391.
5. Swenson DL, Warfield KL, Warren TK, Lovejoy C, Hassinger JN, Ruthel G, Blouch RE, Moulton HM, Weller DD, Iversen PL, Bavari S. 2009. Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection. Antimicrob Agents Chemother 53: 2089-2099. http://dx. doi. org/10. 1128/AAC. 00936-08.
6. Warren TK, Warfield KL, Wells J, Swenson DL, Donner KS, Van Tongeren SA, Garza NL, Dong L, Mourich DV, Crumley S, Nichols DK, Iversen PL, Bavari S. 2010. Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat Med 16: 991-994. http://dx. doi. org/10. 1038/nm. 2202.
7. Ramanan P, Shabman RS, Brown CS, Amarasinghe GK, Basler CF, Leung DW. 2011. Filoviral immune evasion mechanisms. Viruses 3: 1634-1649. http://dx. doi. org/10. 3390/v3091634.
8. Xu W, Edwards MR, Borek DM, Feagins AR, Mittal A, Alinger JB, Berry KN, Yen B, Hamilton J, Brett TJ, Pappu RV, Leung DW, Basler CF, Amarasinghe GK. 2014. Ebola virus VP24 targets a unique NLS binding site on karyopherin alpha 5 to selectively compete with nuclear import of phosphorylated STAT1. Cell Host Microbe 16: 187-200. http://dx. doi. org/10. 1016/j. chom. 2014. 07. 008.
9. Basler CF, Wang X, Mühlberger E, Volchkov V, Paragas J, Klenk HD, García-Sastre A, Palese P. 2000. The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc Natl Acad Sci U S A 97: 12289-12294. http://dx. doi. org/10. 1073/pnas. 220398297.
10. Reid SP, Leung LW, Hartman AL, Martinez O, Shaw ML, Carbonnelle C, Volchkov VE, Nichol ST, Basler CF. 2006. Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J Virol 80: 5156-5167. http://dx. doi. org/10. 1128/JVI. 02349-05.
11. National Research Council. 1996. Guide for the care and use of laboratory animals. National Academies Press, Washington, DC.
12. Iversen PL, Warren TK, Wells JB, Garza NL, Mourich DV, Welch LS, Panchal RG, Bavari S. 2012. Discovery and early development of AVI-7537 and AVI-7288 for the treatment of Ebola virus and Marburg virus infections. Viruses 4: 2806-2830. http://dx. doi. org/10. 3390/v4112806.
13. Bradfute SB, Bavari S. 2011. Correlates of immunity to filovirus infection. Viruses 3: 982-1000. http://dx. doi. org/10. 3390/v3070982.
14. Mateo M, Carbonnelle C, Reynard O, Kolesnikova L, Nemirov K, Page A, Volchkova VA, Volchkov VE. 2011. VP24 is a molecular determinant of Ebola virus virulence in guinea pigs. J Infect Dis 204(Suppl 3): S1011-S1020. http://dx. doi. org/10. 1093/infdis/jir338.
15. Watt A, Moukambi F, Banadyga L, Groseth A, Callison J, Herwig A, Ebihara H, Feldmann H, Hoenen T. 2014. A novel life cycle modeling system for Ebola virus shows a genome length-dependent role of VP24 in virus infectivity. J Virol 88: 10511-10524. http://dx. doi. org/10. 1128/JVI. 01272-14.
16. Heald AE, Iversen PL, Saoud JB, Sazani P, Charleston JS, Axtelle T, Wong M, Smith WB, Vutikullird A, Kaye E. 2014. Safety and pharmacokinetic profiles of phosphorodiamidate morpholino oligomers with activity against Ebola virus and Marburg virus: results of two singleascending-dose studies. Antimicrob Agents Chemother 58: 6639-6647. http://dx. doi. org/10. 1128/AAC. 03442-14.